


eISSN: 1879-6648
ISSN: 2452-3267
eISBN: 978-1-68108-163-2
ISBN: 978-1-68108-164-9

Frontiers in Cardiovascular Drug Discovery

Volume 3



Editors:
Atta-ur-Rahman, FRS
M. Iqbal Choudhary

Bentham  Books

Frontiers in Cardiovascular Drug Discovery

(Volume 3)

Edited by

Atta-ur-Rahman, *FRS*

Kings College

University of Cambridge

Cambridge

UK

&

M. Iqbal Choudhary

H.E.J. Research Institute of Chemistry

International Center for Chemical and Biological Sciences

University of Karachi

Karachi

Pakistan

Frontiers in Cardiovascular Drug Discovery

Volume # 3

Editors: Atta-ur-Rahman and M. Iqbal Choudhary

ISSN (Online): 1879-6648

ISSN (Print): 2452-3267

ISBN (eBook): 978-1-68108-163-2

ISBN (Print): 978-1-68108-164-9

©2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2
PO Box 7917, Saif Zone
Sharjah, U.A.E.
Email: subscriptions@benthamscience.org



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iv
CHAPTER 1 P2Y12-RECEPTOR ANTAGONISTS AND THE CONCEPT OF TAILORED STRATEGY...	3
<i>O ctqwpg'Dqwnj tku'U'ncxqt g'F0Vqo cugntq.'\ kgf 'Kdp'Gj cfl'cpf 'Crt gf q'T0I cr:uak</i>	
INTRODUCTION	4
ADP RECEPTORS	6
P2Y12 RECEPTOR	7
P2Y12 INHIBITORS	9
Thienopyridines	14
<i>Ticlopidine</i>	14
<i>Clopidogrel</i>	16
<i>Prasugrel</i>	20
<i>Ticagrelor</i>	22
<i>Cangrelor</i>	26
<i>Elinogrel</i>	28
BX 667	30
THE CONCEPT OF PERSONALIZED THERAPY	30
Factors Influencing Clopidogrel Variability	31
Anti-Platelet Function Testing	33
<i>Platelet Aggregometry</i>	35
<i>Flow Cytometry</i>	36
<i>Shear-Dependent Assay</i>	36
<i>Platelet Counting</i>	37
<i>Thrombelastography</i>	37
<i>Anti-Platelet Function Testing & Clinical Impact</i>	37
<i>Genotype Testing</i>	40
<i>Genetic Testing & Clinical Impact</i>	41
<i>Inter-Individual Variability of New P2Y12 Inhibitors</i>	42
<i>Personalized Therapy</i>	43
CONCLUSION	46
ABBREVIATIONS	46
CONFLICT OF INTEREST	47
ACKNOWLEDGEMENTS	47
REFERENCES	47
CHAPTER 2 EVOLUTION OF HEART FAILURE PHARMACOTHERAPY	62
<i>I wrrtggv'Ujfk'k'Lw'Mko.'Ugrjgp'Tqdkg'cpf'I wmwjgt'Replcvj</i>	
INTRODUCTION	63
CHRONIC SYSTOLIC HEART FAILURE	69
β -Blockers	69
<i>Beta Blockers and Special Populations</i>	73
Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs)	77
Diuretics	83
Aldosterone Antagonists	87
Digoxin	89
Hydralazine/Isosorbide Dinitrate	92
Ivabradine	95
Polyunsaturated Fatty Acids (PUFA)	97
Statins	99

ACUTE DECOMPENSATED HEART FAILURE	102
Classification	103
Management	104
<i>Diuretics</i>	104
<i>Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs)</i>	105
<i>β-blockers</i>	106
<i>Aldosterone Antagonists</i>	107
<i>Vasopressin Antagonists</i>	108
<i>Vasodilators</i>	108
<i>Natriuretic Peptides</i>	109
<i>Inotropes</i>	110
<i>Novel Agents for Acute Decompensated Heart Failure in Development</i>	112
HEART FAILURE WITH PRESERVED EJECTION FRACTION	116
β -Blockers	118
Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs)	119
Calcium Channel Blockers	121
Digoxin	122
Aldosterone Antagonists	122
MISCELLANEOUS DRUG THERAPIES	123
CONCLUSION	126
CONFLICT OF INTEREST	126
ACKNOWLEDGEMENTS	126
REFERENCES	126

CHAPTER 3 VASOPRESSIN AND THE CARDIOVASCULAR SYSTEM: RECEPTOR PHYSIOLOGY AND CLINICAL IMPLICATIONS 148

Co k'Ci tcy cn

INTRODUCTION	149
HISTORICAL ASPECTS	150
PHYSIOLOGY OF VASOPRESSIN	151
Structure of Vasopressin and Related Peptides	151
<i>Structure of Vasopressin</i>	151
<i>Structure of Related Peptides</i>	153
Synthesis of Vasopressin	155
Metabolism	156
Factors Affecting Vasopressin Release	156
<i>Osmoregulation</i>	157
<i>Baroregulation</i>	158
<i>Neurohormonal Stimuli</i>	158
Plasma Levels of Vasopressin	159
<i>Vasopressin Levels in Health</i>	159
<i>Vasopressin Levels During Illness</i>	160
<i>Measurement of Plasma Vasopressin Levels</i>	161
Vasopressin Receptors	162
<i>Receptor Structure</i>	162
<i>Receptor Subtypes</i>	162
<i>V1A Receptor</i>	165
<i>V1B or V3 Receptor</i>	167
<i>V2 Receptor</i>	168
<i>Oxytocin Receptor</i>	169
<i>Purinergic Receptors</i>	170
<i>Down Regulation of Vasopressin Receptors</i>	171

Systemic Effects of Vasopressin	172
<i>Renal Effects</i>	172
<i>Vasoconstrictor Effects</i>	173
<i>Vasodilator Effects</i>	175
Effects of Vasopressin on Heart	175
<i>Endocrine Effects</i>	177
<i>Effects on Coagulation System</i>	177
<i>Other Effects</i>	178
Therapeutic Applications of Vasopressin	179
<i>Nocturnal Enuresis</i>	179
<i>Diabetes Insipidus</i>	180
<i>Bleeding Abnormalities</i>	180
<i>Oesophageal Varices Haemorrhage</i>	180
<i>Abdominal Distension & Abdominal X-ray</i>	181
<i>Vasodilatory Shock States</i>	181
<i>Hemorrhagic Shock</i>	185
<i>Other Uses</i>	189
Future	192
CONFLICT OF INTEREST	193
ACKNOWLEDGEMENTS	194
REFERENCES	194

CHAPTER 4 CEREBRAL SMALL VESSEL DISEASE: A CLINICAL REVIEW FOCUSING ON THERAPEUTIC STRATEGIES 219

<i>Нісрєкєєq'Lqu² "f'кct g/R²tg/</i>	
CONCEPT OF CEREBRAL SMALL VESSEL DISEASE	220
ANATOMY OF CEREBRAL SMALL VESSELS	221
Central System	221
Cortical System	222
<i>Conducting Arteries</i>	222
<i>Distributing Arteries</i>	222
CLASSIFICATION OF CEREBRAL SMALL VESSEL DISEASES	223
PATHOLOGY OF TYPES 1 AND 2 CEREBRAL SMALL VESSEL DISEASES	225
Type 1 Cerebral Small Vessel Disease (Arteriolosclerosis)	225
<i>Vascular Changes</i>	225
<i>Parenchymatous Changes</i>	227
Type 2 Cerebral Small Vessel Disease (Sporadic and Hereditary Cerebral Amyloid Angiopathy)	229
CLINICAL MANIFESTATIONS OF CEREBRAL SMALL VESSEL DISEASE	229
Deep Brain Infarcts	230
White Matter Lesions	231
Deep Intracerebral Haemorrhages	232
Cerebral Microbleeds	233
Others Markers of Cerebral Small Vessel Disease: Brain Atrophy and Enlarged Perivascular Spaces	234
DIAGNOSIS OF CEREBRAL SMALL VESSEL DISEASE	234
Imaging Studies	235
<i>Computed Tomography</i>	235
<i>Magnetic Resonance Imaging</i>	236
<i>Transcranial Doppler Study</i>	242
<i>Biomarkers as In-vivo Markers of Small Vessel Disease</i>	244
TREATMENT OF CEREBRAL SMALL VESSEL DISEASE	245
Ischemic Stroke Caused by Small Vessel Disease: Acute Treatment and Secondary Prevention	246
<i>Thrombolysis</i>	246

<i>Secondary Prevention of Ischemic Stroke in Patients with Cerebral Small Vessel Disease</i>	247
Symptomatic Treatment of Cognitive Impairment in Patients with Cerebral Small Vessel Disease	254
<i>Memantine</i>	254
<i>Acetylcholinesterase Inhibitors</i>	254
<i>Other Drugs</i>	257
<i>Novel Approaches For Treatment of Cerebral Small Vessel Disease</i>	261
CONCLUSIONS	263
CONFLICT OF INTEREST	264
ACKNOWLEDGEMENTS	264
REFERENCES	264

CHAPTER 5 **COMPLEMENT BLOCKING THERAPEUTIC STRATEGIES: A PROSPECTIVE APPROACH FOR THE TREATMENT OF CARDIOVASCULAR DISEASES**

[cy 'Cuct g.'Ucpqij 'Xklc{cp.'T cpwxf 'Uj ci fctwt gp'cpf 'Gtf gpgej ko gi 'Uj ci fctwt gp

1. COMPLEMENT ACTIVATION CASCADE AND PATHWAYS	281
1.1. Classical Pathway of Complement Activation	281
1.2. Mannose-Binding Lectin (MBL) Pathway	283
1.3. Alternative Pathway of Complement Activation	284
1.4. Complement Anaphylatoxins	284
1.5. Complement Anaphylatoxin Receptors	286
2. NATURALLY OCCURRING COMPLEMENT INHIBITORS AND REGULATORS	287
2.1. Natural Regulators at the Early level of Complement Activation	287
<i>C1-Esterase Inhibitor</i>	287
2.2. Natural Regulators at the C3-Convertase Level	289
<i>Complement Receptors (CRs)</i>	290
2.3. Natural Regulators at the C5-Convertase Level	292
3. COMPLEMENT INHIBITORS/REGULATORS AS THERAPEUTICS	293
3.1. C1-esterase Inhibitor (C1-INH)	293
3.2. Inhibitors at the C3 Convertase Level	294
<i>CR2-fH and mAb 1379</i>	295
3.3. Inhibitors at the C5 Convertase Level and Formation of MAC	296
<i>Pexelizumab and Eculizumab</i>	296
4. COMPLEMENT SYSTEM IN ATHEROSCLEROSIS-RELEVANT CELL TYPES	296
4.1. Complement Activation in Vascular Endothelial Cells	296
4.2. Vascular Smooth Muscle Cells and the Complement Activation	299
4.3. Macrophages and Complement Activation	301
4.4. Interplay between Platelets and the Complement Cascade	302
4.5. Lipids and Complement	303
5. COMPLEMENT SYSTEM IN ATHEROSCLEROSIS	304
5.1. Atherosclerosis and Complement-mediated Effects in the Vasculature	304
5.2. Targeting Complement System in Experimental Atherosclerosis	306
5.3. Intervening Human Atherosclerosis via Complement Blocking Strategies	309
5.4. Complement As Circulating Biomarkers	310
6. COMPLEMENT AND MYOCARDIAL INFARCTION	311
6.1. Complement System is Activated in Myocardial Infarction	311
6.2. Complement Inhibition with C1-INH by MI and Myocardial IR-Injury	313
6.3. Complement Inhibition at C3 Convertase Level in MI	315
6.4. Complement Inhibition at C5 level with Anti-C5 Antibodies (Eculizumab) in MI	316
6.5. Inhibiting MBL-Pathway	319
6.6. Complement Inhibition at Effector Levels using C5a Receptor 1 Inhibitors	319
7. FUTURE OF COMPLEMENT INHIBITING THERAPEUTIC STRATEGIES	322
CONFLICT OF INTEREST	323

ACKNOWLEDGEMENTS	323
REFERENCES	323
CHAPTER 6 NEW ANTIPLATELET AND ANTICOAGULANT AGENTS: TOWARDS RECOGNITION AND REDUCTION OF GASTROINTESTINAL HARM	347
<i>Rctvj 'LORctgnj . 'Gfy ctf 'E0Qtf hkgf 'K'c'pf 'F cxf 'COLqj puqp</i>	
INTRODUCTION	348
PHARMACOLOGY OF AVAILABLE ANTIPLATELET AGENTS	348
Aspirin	348
Thienopyridines– Clopidogrel, Prasugrel, and Ticagrelor	349
BLEEDING RISK OF AVAILABLE ANTIPLATELET AGENTS	350
Aspirin	351
Thienopyridines– Clopidogrel, Prasugrel, and Ticagrelor	352
Current Strategies Towards Recognition and Reduction of Gastrointestinal Harm	352
<i>Chemoprophylaxis – Who to Treat? What Agents to Use? What is the Role of Helicobacter Pylori?</i>	
.....	353
PHARMACOLOGY OF TRADITIONAL AND NOVEL ANTI-COAGULANTS	356
Warfarin	356
Direct Thrombin Inhibitors - Dabigatran	357
Factor Xa Inhibitors - Rivaroxaban and Apixaban	358
BLEEDING RISK OF TRADITIONAL AND NOVEL ANTICOAGULANTS	359
Warfarin	359
Dabigatran, Rivaroxaban, and Apixaban	360
Drug Monitoring (nOACs)	365
Reversal Strategies and Clinical Management of nOACs	366
CONCLUSION	370
ABBREVIATIONS	370
CONFLICT OF INTEREST	371
ACKNOWLEDGEMENTS	371
REFERENCES	371
SUBJECT INDEX	380

PREFACE

Cardiovascular diseases are the major cause of morbidity and mortality in humans. Despite major advancements in cardiovascular drug discovery and development, heart diseases and stroke remain the leading public health concern and primary causes of death globally. The development of effective and safe medicines that control blood pressure and cholesterol has significantly reduced the death rate from heart diseases. However, with global rise in metabolic disorders and aging populations, the prevalence of hypertension, high cholesterol, and diabetes is increasing. Heart diseases and stroke are becoming a worldwide pandemic as developing nations are witnessing the increasing health burden caused by them. To tackle this problem, tremendous research work has been conducted to understand the cause of cardiovascular diseases at molecular levels. This has led to the identification of new drug targets which are now vigorously studied.

The 3rd volume of the ebook series, “*Frontiers in Cardiovascular Drug Discovery*” comprises six comprehensive reviews, contributed by leading experts in these fields. Each review is focused on a certain important aspect of cardiovascular drug discovery and development, including the identification of new molecular targets and the outcome of clinical studies.

Boukhris *et al.* have contributed a review on P2Y₁₂ receptor antagonists as efficient treatment of platelet dysfunctions, including platelet aggregation and thrombus formation. The authors have comprehensively reviewed the role of P2Y₁₂ receptors in thrombus formation, and the mechanism of action of various classes of P2Y₁₂ receptor antagonists as anti-platelets agents. They also present the literature pertaining to the clinical outcome of efficacy and safety of various new generation of anti-platelet drugs, as well as prospects of tailored or individualized anti-platelet therapy for improving the clinical outcome.

Various forms of acute heart failures are heterogeneous in nature. They are difficult to manage and the conditions are often difficult to treat. The development of pharmacotherapy of acute heart failures has been comprehensively reviewed by Panjra *et al.* in Chapter 2. The authors review the various classes of drugs and their contributions in reducing the mortality due to acute heart failure. The development of new therapeutic agents under the new regulatory requirements is also discussed, along with potential future developments in heart failure management and treatment.

Amit Agrawal reviews the role of vasopressin (arginine vasopressin) in cardiovascular health. Vasopressin is an anti-diuretic hormone which performs many essential functions in the body including maintaining plasma osmolality and volume. It has a direct impact on cardiovascular functions. A key function of AVP in the body is to regulate the extracellular fluid volume by

regulating the renal handling of water. Vasopressin acts on renal collecting ducts *via* V₂ receptors to increase water permeability (cAMP-dependent mechanism), which leads to decreased urine formation and thus increases the blood volume, cardiac output, and arterial pressures. Over the years, synthetic vasopressin has emerged as an important drug for the treatment of various shock states. The author has elegantly reviewed various uses of vasopressin in critical care, especially in the treatment of vasodilatory shock. The commentary on mechanism of action of vasopressin at molecular and receptor levels provides insight into the action of this smart drug which is finding new uses with every passing day.

Cerebral small vessel disease (CSVD) or microangiopathy is a group of diseases involving microangiopathy and unspecific arteriopathy. This is a common risk factor for cognitive impairment, characterized by hypertrophy, vascular modification, and endothelial dysfunction that alter cerebrovascular functions, and auto-regulation of cerebral blood flow. CSVDs increase the risk of ischemia and tissue bleeding and may be categorized into six classes, based on the tissue types that they affect. The review by Alvarez-Perez focuses on type 1 CSVD, which is among the most common conditions, also called arteriolosclerosis. It is associated with aging, arterial hypertension, and diabetes. The author reviews the literature on the etiology and treatment of type 1 CSVD. Various classes of anti-aggregant drugs (aspirin, ticlopidine, and aspirin plus other drugs) have shown efficacy in this condition. The results of clinical studies on various classes of drugs have been discussed in this excellent review.

Shagdarsuren *et al.* have contributed a review on recent developments on a novel class of therapeutic agents which block and disable the complement blocking system. The complement cascade is an integral component of the body's innate immune system, which boosts the capacity of antibodies and phagocytic cells to clear the invading microorganisms and damaged cells from the body. The complement system is involved in promoting inflammation in various pathological conditions. Most importantly, the complement cascade is known to be involved in obesity, fatty liver, diabetes and cardiovascular diseases (CVD). The complement system comprising several complex small proteins and their receptors, is known to be activated in cardiovascular diseases. This has attracted major scientific interests in various complement molecules /components as new therapeutic targets. The authors present an excellent commentary on various complement molecules, their primary and secondary receptors, and their functional roles in the onset and progression of CVDs. They have also summarized the beneficial results observed in various pre-clinical studies conducted on targeting of specific components of the complement system in CVD animal models. This new class of drugs which includes gene targeting agents, neutralizing antibodies, and small molecular inhibitors, holds great promise for the treatment of CVDs in future.

Antiplatelet and anticoagulant therapies are essential parts of cardiovascular and cerebrovascular diseases prevention and management. They are among the most difficult

classes of therapies, where balancing the benefits of antiplatelet and anticoagulant drugs with the risk of gastrointestinal and other bleedings is a major challenge. Aspirin and warfarin have been the most frequently used medicines for this purpose, with high risks of bleeding, and other therapeutic limitations. Recently, several novel classes of antiplatelet and anticoagulant agents have been developed which specifically target the mechanism of coagulation pathways, and thus have improved therapeutic efficacy. These new drugs are also associated with the occurrence of bleedings, including gastrointestinal bleeding. Johnson *et al.* have reviewed the recent literature on the pharmacology of available antiplatelet and anticoagulant drugs, particularly with reference to the associated risks, such as gastrointestinal bleeding and toxicity. They have also provided data about currently available and in pipeline anticoagulant reversal agents. This review is therefore an excellent source of information about the merits and demerits of new antiplatelet and anticoagulant agents, as well as development of agents which can reverse the bleeding episodes as a result of anticoagulant therapies.

The editors wish to express profound gratitude to all the contributors for the timely submission of their review articles for the 3rd volume of the eBook series. We also appreciate the efforts of the entire team of Bentham Science Publishers for efficient processing. The efforts of Mr. Omer Shafi (Assistant Manager Publications), Mr. Shehzad Naqvi (Manager Publications) and team leader Mr. Mahmood Alam (Director Publications) for their assistance in putting together an excellent compilation of well written articles in this important field of biomedical research. We sincerely hope that this volume will receive wide appreciation from readers.

Dr. Atta-ur-Rahman

Kings College
University of Cambridge
Cambridge
UK
&

Dr. M. Iqbal Choudhary

H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Karachi
Pakistan

List of Contributors

Alfredo R. Galassi	Department of Medical Sciences and Pediatrics, Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Cannizzaro Hospital, University of Catania, Italy
Amit Agrawal	Gandhi Medical College & Hamidia Hospital, Bhopal, MP, India
David A. Johnson	Department of Internal Medicine, Division of Gastroenterology and Hepatology, Eastern Virginia Medical School, Norfolk, USA
Edward C. Oldfield	Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, USA
Erdenechimeg Shagdarsuren	Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen, Germany
Francisco José Álvarez-Pérez	Medicine Department, Health Sciences Research Center, Sciences Faculty, Beira Interior University, Stroke Unit, Hospital of Covilha, Covilha, Portugal
Gansuud Shagdarsuren	Department of Internal Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia
Gurpreet Sodhi	Department of Medicine (Cardiology) and Heart and Vascular Institute, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA
Gurusher Panjra	Department of Medicine (Cardiology) and Heart and Vascular Institute, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA
Ju Kim	Department of Medicine (Cardiology) and Heart and Vascular Institute, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA
Marouane Boukhris	Department of Medical Sciences and Pediatrics, Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Cannizzaro Hospital, University of Catania, Italy Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia
Parth J. Parekh	Department of Internal Medicine, Division of Gastroenterology and Hepatology, Tulane University, New Orleans, USA
Salvatore D. Tomasello	Department of Medical Sciences and Pediatrics, Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Cannizzaro Hospital, University of Catania, Italy
Santosh Vijayan	Institute for Translational Immunology, University Hospital, Johannes Gutenberg-University Mainz, Germany

- Stephen Robie** Department of Medicine (Cardiology) and Heart and Vascular Institute, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA
- Yaw Asare** Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians University, Munich, Germany
- Zied Ibn Elhadj** Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia

P2Y₁₂-Receptor Antagonists and the Concept of Tailored Strategy

Marouane Boukhris^{1,2,*}, Salvatore D. Tomasello¹, Zied Ibn Elhadj² and Alfredo R. Galassi¹

¹ Department of Medical Sciences and Pediatrics, Catheterization Laboratory and Cardiovascular Interventional Unit, Division of Cardiology, Cannizzaro Hospital, University of Catania, Italy

² Faculty of Medicine of Tunis, University of Tunis El Manar, Tunisia

Abstract: Platelet represents the cornerstone of both physiologic hemostasis and thrombosis acting *via* different pathways. Adenosine diphosphate (ADP) plays a crucial role in platelet activation and thrombus formation through its interaction with platelet P2Y₁₂ receptor, making therefore this receptor an interesting therapeutic target for anti-thrombotic agents.

Around the world, millions of people affected by coronary artery disease are treated with anti-platelet agents. Indeed, dual anti-platelet therapy, consisting of a combination of aspirin and a P2Y₁₂ receptor antagonist, is the recommended strategy in patients with acute coronary syndrome and those who underwent percutaneous coronary intervention with stent implantation. Furthermore, the introduction of different generations of P2Y₁₂ receptor antagonists has immensely improved the clinical outcome, as well established through literature.

Although the concept to replace “one size fits all” paradigm to a more individualized approach in anti-platelet therapy seems to be rational, in the area of based evidence medicine, a clear prognostic impact of such a strategy is not yet clearly demonstrated.

In the current chapter, we tried to summarize the mechanisms of P2Y₁₂ receptor antagonists anti-platelet action, to report clinical proofs regarding the efficacy/safety of

* **Corresponding Author Marouane Boukhris:** Department of Medical Sciences and Pediatrics Catheterization Laboratory and Cardiovascular Interventional Unit Cannizzaro Hospital, University of Catania *Via* Messina 829, 95126, Catania, Italy; Tel: 0039-095-7263122-3623; Fax: +39-095-72631-4-3633; E-mail: mar1bou@hotmail.com

new generations of this class of drugs, and to discuss the place of a tailored strategy and its impact on improving clinical outcome.

Keywords: Anti-aggregation therapy, Bleeding, Cangrelor, Clinical outcome, Clopidogrel, Coronary artery disease, Dual anti-platelet therapy, Elinogrel, Genetic testing, High on-treatment platelet reactivity, Ischemic event, Low on-treatment platelet reactivity, Percutaneous coronary intervention, Platelet aggregation, Platelet reactivity, Prasugrel, P2Y12 receptor, P2Y12 receptor inhibitors, Stent implantation, Ticagrelor.

INTRODUCTION

The primary function of platelets is to preserve vascular integrity and hemostasis; however, in presence of vascular disease, particularly atherosclerosis, this normal process can become excessive, leading to thrombotic events. The role of platelets in the pathophysiology of arterial thrombosis has been investigated over the past decades and established as crucial [1 - 3]. Platelet-dependent thrombotic events such as myocardial infarction (MI), stroke and even sudden cardiac death, often started by an acute plaque destabilization followed by platelet adhesion, activation and aggregation, which represented the key processes. Indeed, differently from normal endothelium platelets only adhere to disrupted endothelial surfaces. Thereafter, platelets undergo shape change, secrete the contents of their granules, transform endogenous arachidonic acid into thromboxane A₂, and aggregate with one another, resulting in a platelet-dependent thrombus [2, 3].

Aspirin represents the first effective platelet inhibitor drug used in humans. It results in an irreversible modification of the enzyme cyclo-oxygenase preventing it to convert arachidonic acid into thromboxane A₂ [4].

On the other hand, adenosine diphosphate (ADP) also plays a capital role in platelet activation. Originating from platelet dense granules, red blood cells and damaged endothelium, its interaction with platelet receptors (particularly P2Y₁₂ receptors), leads to an activation-amplification cascade resulting in thrombus formation [5]. This capital role of ADP makes it an appropriate therapeutic target for anti-platelet agents acting differently from aspirin. In this respect, P2Y₁₂ receptor antagonists had been introduced in cardiovascular diseases (Fig. 1).




Fig. (1). Platelet activation and the mechanism of action of different anti-platelet agents.

Nowadays, around the world, millions of people affected by coronary artery disease (CAD), are treated with antiplatelet agents. Indeed, dual anti-platelet therapy (DAPT), consisting of a combination of aspirin and a P2Y12 receptor antagonist is the recommended strategy in patients with acute coronary syndrome (ACS) and those who underwent percutaneous coronary intervention (PCI) with stent implantation [6]. Furthermore, the introduction of new generations of P2Y12 receptor antagonists has immensely improved the clinical outcome,

During the last decade, the interest in platelet reactivity testing has grown, with the aim to obtain a tailored and personalized anti-aggregation strategy. However, the prognostic impact of such an approach remains not yet clearly demonstrated.

In the current chapter, we tried to summarize the mechanisms of P2Y12 receptor antagonists anti-platelet action, to report clinical proofs regarding the

Evolution of Heart Failure Pharmacotherapy

Gurpreet Sodhi, Ju Kim, Stephen Robie and Gurusher Panjra^{*}

Department of Medicine (Cardiology) and Heart and Vascular Institute, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA

Abstract: Heart Failure is a chronic disease with increasing prevalence around the world. It is associated with significant mortality, morbidity, and healthcare costs. Over the past 2-3 decades, major advances in drug development have contributed significantly in decreasing mortality among those with chronic systolic heart failure. However, similar advances are missing in patients experiencing acute heart failure and heart failure with preserved ejection fraction. In the current chapter, we will review the historical development of pharmacotherapy in heart failure medical management. A comparative review of contribution of each class towards reducing mortality will be performed. More importantly, drugs which failed to succeed or impact significantly will be reviewed and an insight on why they may have failed will be provided. Development of new drugs is limited by regulatory requirements as well as disease heterogeneity. New agents under development will be summarized and mode of their action will be detailed. This chapter aims to serve as a comprehensive resource on strategies both past and current as well as provide discussion regarding potential future developments in heart failure pharmacotherapy.

Keywords: ACE inhibitors, Aldosterone antagonists, Beta blockers, BiDil, Diastolic dysfunction, Digoxin, Diuretics, Dobutamine, Heart decompensation, Heart failure, History, Ibopamine, Ivabradine, Milrinone, Natriuretic peptides, Novel therapies, Pharmacology, Statin, Systolic dysfunction, Vasodilator.

^{*} **Corresponding Author Gurusher Panjra:** Department of Medicine (Cardiology) and Heart and Vascular Institute, The George Washington University School of Medicine and Health Sciences, Washington D.C., USA; Tel: 202-74-2323; Fax: 202-741-2324; E-mail: gpanjra@mfa.gwu.edu

INTRODUCTION

The collection of symptoms that are regarded as the syndrome of ‘congestive heart failure’ have been reported since the era of Hippocrates, who made note of the physical signs of pulmonary congestion: ‘When the ear is held to the chest, and one listens for some time, it may be heard to see the inside like the boiling of vinegar’ [1]. From the beginning, disordered fluid balance was a key component to the clinical understanding of what would develop into congestive heart failure. As our understanding of heart failure and the complexity of the body’s response has evolved, so has the development of pharmacologic treatment. To understand the evolution of therapeutic treatment options, one must appreciate the development of our understanding of the disease itself.

When viewing the progression of heart failure therapeutics retrospectively, one may successfully divide our understanding of the disease etiology into three general models: cardiorenal, cardiocirculatory, and neurohormonal [1]. Of course, these models came into play when it was clear that the heart was indeed the center of pathology. This concept was not entirely clear for several centuries [1]. Until Harvey’s revelation regarding circulation, the physiologic function of the heart was not entirely well understood [1, 2]. Thus, the concept of disordered fluid balance, independent of the crucial role played by the heart and the cardiovascular system, with the accompanying symptoms of swelling and shortness of breath, dominated pathophysiologic understanding for several years [1].

As our initial understanding of the disease process focused upon the outward symptomatic manifestations of heart failure, symptomatic relief was focused on the management of anasarca or, as it was so commonly referred to, ‘dropsy’ [1]. Volume control at any cost was the predominate concentration of treatment. The focus on the volume sequelae of congestive heart failure is a predominant focus of the ‘cardiorenal’ model of heart failure. Hence, the earliest attempts at pharmacologic therapy would attempt to manipulate this pathophysiologic pathway [1]. Medications were primarily judged on their ability to reduce total body volume. This was often done with no clear understanding of the drugs’ true mechanisms of action or effects. Treatments such as foxglove (modern day *Digitalis*) were utilized on the observation of their therapeutic effects with little

appreciation for their underlying machinations [2]. Diuretics, in some primitive form or another, were utilized with great frequency. Prior to their advent, reduction in circulating volume, whether *via* diaphoretics, purgatives, or direct blood letting, were commonplace [1, 3]. Some attempts to reduce swelling even went so far as to utilize external mechanical measures such as ‘congesting cuffs’, the practice of applying tourniquets to the peripheral extremities, in an attempt to capture volume in the periphery and decrease pulmonary pressures [3]. These efforts were not necessarily due to poor scientific approach *per se*. Indeed, they often made sense given the limited understanding of pathophysiology at the time. However, work clearly needed to be done to move beyond the simplistic external observations that initially drove the cardiorenal era.

The concept of ‘dropsy of the chest’ came into view during the 17th century [3]. The heart’s role was not widely regarded in the syndrome until vivisection became more prevalent and an understanding of structural heart disease developed in the 18th century [1, 3]. A clear differentiation of cardiac and renal etiologies were developed by John Blackall and Richard Bright during this time period [3]. Though there existed primitive manifestations of modern medications such as foxglove, therapies up to the advent of the second world war were frequently of limited therapeutic benefit and had a high index of toxicity [4, 5]. The earliest forms of diuretics had high toxic potential and commonly included the use of organic mercurials [4]. Primitive diuretics provided much needed symptom relief but the natural history and progression of heart failure, their mechanisms and existence not quite characterized at this time, were not impeded by these therapies [1, 3, 4]. As such, researchers continued to search for additional theoretical models that explained not only symptom development, but also disease progression.

In 1833, Bertin was one of the first to note that dilatation ‘weakens the contractile power of the muscular substance’, but the direct correlation with dropsy remained elusive [1]. Still, this focus on the structural consequences upon the heart in congestive heart failure was tantamount. With the prevalence of rheumatic heart disease and infectious valvulopathies like syphilis, the initial understandings of heart failure pathology were limited largely to structural heart disease [1, 6]. In the first half of the 20th century, nearly three quarters of all heart disease in

Vasopressin and the Cardiovascular System: Receptor Physiology and Clinical Implications

Amit Agrawal*

Gandhi Medical College & Hamidia Hospital, Bhopal, MP, India

Abstract: Arginine vasopressin or antidiuretic hormone has got name “vasopressin” due to its vasoconstrictor properties. Vasopressin is a posterior pituitary hormone which is essential for the cardiovascular homeostasis. In normal physiological conditions, it helps in regulation of plasma osmolality and volume *via* its action on the kidney. Other important actions of vasopressin include regulation of vascular smooth muscle tone, control of circadian rhythm, thermoregulation, and adrenocorticotrophic hormone release (ACTH).

In recent years, vasopressin has emerged as an important therapeutic option in the treatment of various shock states. Vasopressin has increasingly been used in both pediatric and adult critical care units for the management of central diabetes insipidus, bleeding abnormalities, oesophageal variceal haemorrhage, asystolic cardiac arrest, and various shock states *e.g.* shock due to ventricular fibrillation, hypovolaemia, sepsis and cardiopulmonary bypass.

Ongoing researches helped in increasing understanding of the endocrine response to shock and importance of vasopressin in their management. Prolonged vasodilatory shock is characterised by relative deficiency of endogenous vasopressin and marked vasopressor effects of the exogenously administered hormone. Sepsis and post cardiopulmonary bypass conditions are the most common causes of vasodilatory shock; however, vasodilation can be a common final pathway of any type of shock. Unlike other vasoconstrictors, vasopressin also exerts some vasodilatory properties which can be due to its action on various receptors, namely V1 vascular, V2 renal, V3 pituitary and oxytocin receptors, and the P2 purinergic receptors producing variable and seemingly contradictory responses.

* **Corresponding author Amit Agrawal:** Gandhi Medical College & Hamidia Hospital, Bhopal, MP, India; Tel: 0755-2680996; E-mail: agrawaldranit@yahoo.co.in

To better understand the variable responses on the vascular system, which vasopressin exerts, it is prudent to acquire the knowledge of the physiology and action of the different vasopressin receptors. In this chapter, vascular actions of vasopressin along with distribution of the classic vasopressin receptors and signalling pathways will be explored.

Keywords: Arginine-vasopressin, Oxytocin receptors, Terlipressin, Vasopressin, Vasopressin receptors.

INTRODUCTION

Arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), is one of the first described and structurally characterized neuropeptide hormones. Vasopressin plays an important role in many peripheral and central functions such as regulation of plasma osmolality and blood pressure through its peripheral actions, and central actions include memory, learning and stress-related disorders. Vasopressin is an important stress hormone that has both vasoactive as well as antidiuretic properties. Since its isolation and synthetic preparation vasopressin has been extensively studied, mainly to treat diabetes insipidus and variceal hemorrhage. The vasoactive properties of vasopressin have become an area of intense research when Landry and colleagues first reported a relative deficiency of vasopressin in septic shock and increase in blood pressure and urine output after infusion of low doses of vasopressin [1, 2]. Now, vasopressin has emerged as an important therapeutic option in the management of septic shock and vasodilatory shock from other causes [3 - 5].

Since its isolation, vasopressin has been extensively studied and found to be useful in the management of enuresis, variceal bleeding, septic shock, and cardiac arrest. Enormous work has been done to demonstrate the complex system of synthesis, storage, secretion and regulation of vasopressin, in addition to its many different functions on specific receptors distributed throughout the body in such a manner as to perform its main effects, the regulation of plasma osmolality and arterial blood pressure, in harmony with several other hormones. However in this chapter, only those clinical uses of vasopressin implicated in cardiovascular homeostasis will be discussed. The initial part will cover the physiology and pharmacology of the hormone including structure and distribution of vasopressin

receptors and their signalling pathways as it is necessary to understand the seemingly paradoxical vasodilatory and vasoconstrictor actions of vasopressin. In the later part of the chapter, the mechanisms of action of vasopressin through different types of receptors leading to vasoconstriction or vasodilation of vascular smooth muscles will be discussed.

HISTORICAL ASPECTS

Vasopressin was first discovered by Oliver & Schafer in 1895 by observing the vasoconstrictor effect of an extract of the posterior pituitary [6]. Human vasopressin contains the amino acid arginine; therefore, it is also named as “Arginine Vasopressin”. In 1906, Sir Henry Dale has discovered another pituitary hormone “oxytocin” by successfully demonstrating the contractions of the mammalian uterus by a component of the pituitary [7]. A few years later in 1913, Farini in Italy and von del Venden in Germany successfully treated the patients of diabetes insipidus by injection of neurohypophysis extract and independently demonstrated its antidiuretic effect [8, 9]. In 1951, Turner *et al.* succeeded in purification of vasopressin preparation and identified the nine amino acid sequences of vasopressin [10]. Two years later in 1953, Acher & Chauvet and du Vigneaud *et al.* proposed the structure of vasopressin [11, 12]. Very soon, the structure of related oxytocin was also identified by Tuppy and du Vigneaud *et al.* [13, 14]. In 1954, du Vigneaud *et al.* first synthesized the vasopressin in a laboratory and proved that both the vasopressor and antidiuretic effects were from the same hormone [15]. For this pioneering work, du Vigneaud also won the Nobel Prize in chemistry in 1955.

Following discovery of structure and amino acid sequences of vasopressin and oxytocin, attention of the researchers have turned to locate the site of synthesis of these hormones in human body. About a decade later, Sachs *et al.* in their studies demonstrated the hypothalamus as the site of synthesis of vasopressin and oxytocin and that from the hypothalamus these hormones are transported to the posterior pituitary [16 - 18]. Pioneering studies by Howard Sachs and his colleagues hypothesized that the vasopressin peptide was formed by the post-translational processing of a precursor protein [16 - 17]. Gainer and colleagues confirmed their hypothesis by reporting the first physical evidence for the

Cerebral Small Vessel Disease: A Clinical Review Focusing on Therapeutic Strategies

Francisco José Álvarez-Pérez*

Medicine Department, Health Sciences Research Center, Sciences Faculty, Beira Interior University, Stroke Unit, Hospital of Covilha, Covilha, Portugal

Abstract: The term cerebral small vessel disease (CSVD) or microangiopathy includes several pathological processes of different aetiologies which cause an increase of wall thickness (basically the basement membrane), a narrowing of the lumen, and a weakening of walls in arterioles, capillaries and venules. These vascular modifications cause a loss of proteins towards the interstice and a slowness of blood flow, increasing the risk of ischemia and tissue bleeding.

The CSVD may be aetiopathogenically classified in 6 types. The CSVD type 1, called arteriolosclerosis, is the most prevalent form and has a 6 to 10 times higher prevalence than stroke. It is related to aging and classical vascular risk factors, like arterial hypertension and diabetes mellitus. This review will focus on type 1 CSVD.

In the brain, the main pathological findings are loss of smooth muscle cells in the media, accumulation of fibrohyaline material, fibrinoid necrosis, and development of microatheromas and Charcot-Bouchard microaneurysms. The parenchymatous consequences of these vessel modifications are both ischemic (white matter lesions, lacunes) and haemorrhagic (microhaemorrhages, intracerebral haemorrhages). The clinical manifestations of arteriolosclerosis include cognitive deterioration, dementia, mood disorders, gait and motor disturbances, lacunar strokes, and disability. *In vivo*, the diagnosis of CSVD is supported by neuroimaging findings (lacunes, leukoaraiosis, white matter lesions, microhaemorrhages), especially by use of magnetic resonance techniques. The role of other biomarkers (plasma and cerebrospinal fluid biochemical parameters, resistance indexes in transcranial Doppler study) is not completely defined.

* **Corresponding author Francisco J. Álvarez-Pérez:** Medicine Department, Health Sciences Research Center, Sciences Faculty, Beira Interior University, Stroke Unit, Hospital of Covilha, Covilha, Portugal; Tel: +351275329002; Fax: +351275329099; E-mails: fjalvarez@fcsaude.ubi.pt, franciscoplus@hotmail.com

In patients with diagnosis of microangiopathy there are three main therapeutic considerations. First, there are specific risks in these patients during standard clinical management of acute ischemic stroke. Several studies showed an increased risk of intracranial bleeding related to thrombolytic therapy for acute stroke and anticoagulant treatment for secondary prevention. Indeed, the presence of leukoaraiosis raised the probability of peri-operative stroke or death in patients who underwent carotid endarterectomy. Second, the symptomatic management of patients with cognitive impairment related to CSVD, which is currently based on memantine and acetylcholinesterase inhibitors used in Alzheimer's disease. Third, the specific therapy directed to vessel pathology and parenchymatous consequences (secondary prevention). Available data support the use of antiaggregant drugs to reduce the risk of recurrence of lacunar strokes. Aspirin, ticlopidine, aspirin plus clopidogrel, dipyridamol plus aspirin, and cilostazol showed efficacy in this subtype of stroke. The optimal control of arterial pressure and cholesterol level also reduces the risk of stroke, independently if mechanism of disease was macro or microvascular. However, the specific drugs and the optimal goals are not defined and ongoing trials are trying to evaluate different drugs and preventive strategies (cilostazol plus aspirin, aggressive versus standard blood pressure control). Considering the specific treatment of vascular pathology, there are few available data. Experimental studies showed that relaxin may increase the arterial distensibility. In humans, one ongoing trial is investigating the efficacy and safety of an anti-amyloid beta monoclonal antibody in patients with probable cerebral amyloid angiopathy (CSVD type 2).

Keywords: Acetylcholinesterase Inhibitors, Antiaggregants, Cerebral Amyloid Angiopathy, Cerebral Microangiopathy, Cerebral Microhaemorrhages, Cerebral Small Vessel Disease, Deep Brain Infarcts, Deep Intracerebral Haemorrhages, Enlarged Perivascular Spaces, Lacunar Stroke, Memantine, Vascular Dementia, White Matter Lesions.

CONCEPT OF CEREBRAL SMALL VESSEL DISEASE

The small vessel diseases are mainly systemic disorders that may affect different organs and areas of the body. In some conditions, the brain can be the main or only target of the disease, but in other disorders the nervous system might not be affected at all. The term cerebral small vessel disease (CSVD) includes the pathological processes affecting small arteries, arterioles, capillaries, and small veins of the brain. These processes increase the wall thickness, reduce the vascular lumen, and cause structural weakness. The parenchymatous results are

both ischemia and haemorrhage [1]. Therefore, the presence of CSVD is associated with a higher risk of developing ischemic and haemorrhagic stroke, cognitive decline, gait disturbances and dementia. Because the small vessels cannot be visualized *in vivo* and only indirect manifestations may be assessed, the most accepted biomarker of CSVD is the presence of white matter lesions, lacunar infarcts, subcortical atrophy, and haemorrhagic lesions on magnetic resonance imaging (MRI) [2].

The extremely high prevalence of CSVD implies that all disorders associated with this pathology represent an important issue for health systems. Cerebral small vessel disease is the basis for nearly 30% of all ischaemic strokes, it is the first cause of vascular dementia, and it probably is the second cause of dementia syndrome and age-related cognitive decline [3].

Currently, the therapeutic approaches to CSVD are a preventive strategy, based on control of some modifiable risk factors, and a symptomatic control of some clinical manifestations. More specific or “curative” treatments are not available.

ANATOMY OF CEREBRAL SMALL VESSELS

The small vessels are penetrating vessels which vascularise the cerebral and cerebellar cortices, deep white matter, basal nuclei, and brain stem. These vessels originate from the circle of Willis, the system formed by the middle, anterior, and posterior cerebral arteries, the basilar artery, and the anterior and posterior communicating arteries. Classically, two kind of penetrating arteries originate from the circle of Willis: central, ganglionic or deep, and cortical, circumference or superficial [4].

Central System

The vessels of the central system emerge from the own circle and the first segment of main cerebral arteries to penetrate perpendicularly into the parenchyma. They consist of: (1) lenticulostriate arteries, originated from the middle and anterior cerebral arteries to irrigate diencephalon, striate and anterior arm of the internal capsule; (2) thalamo-perforating branches, originated from the posterior cerebral artery to irrigate the thalamus. The anterior and posterior

Complement Blocking Therapeutic Strategies: A Prospective Approach for the Treatment of Cardiovascular Diseases

Yaw Asare¹, Santosh Vijayan², Gansuud Shagdarsuren³ and Erdenechimeg Shagdarsuren^{4,*}

¹ Institute for Stroke and Dementia Research, Klinikum der Universität München, Ludwig-Maximilians University, Munich, Germany

² Institute for Translational Immunology, University Hospital, Johannes Gutenberg-University Mainz, Germany

³ Department of Internal Medicine, School of Medicine, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

⁴ Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen, Germany

Abstract: Despite huge improvements in clinical diagnosis as well as numerous options in patient care and treatment, the incidence of cardiovascular disease (CVD) has been on the rise in the last decade potentially due to hitherto deteriorating lifestyle. As a chronic inflammatory response of the arterial vessel wall, atherosclerosis and its clinical sequelae such as coronary heart disease, cerebrovascular disease and peripheral artery disease continue to be the leading causes of morbidity and mortality worldwide. This makes it necessary to explore novel therapeutic strategies to control and manipulate the mediators of atherosclerosis and cardiac repair processes in order to help combat cardiovascular events. The complement system, an important part of the innate immune response, constitutes a complex network of plasma proteins and membrane cofactors which act in concert with other immunological systems of the body for a rapid defense against foreign intrusions and infections. Activation of the complement cascade in CVD is well established. Numerous well-conducted studies on

* **Corresponding author Erdenechimeg Shagdarsuren:** Institute for Molecular Cardiovascular Research (IMCAR), University Hospital, RWTH Aachen, Germany, Pauwelsstraße 30, 52074 Aachen, Germany; Tel: +49-241-8036584; Fax: +49-241-8082703; Email: eguenther@ukaachen.de.

targeting specific components of the complement cascade in CVD have opened avenues for targeted pharmacological inhibition of the complement system at different levels of complement activation. The use of gene targeting and neutralizing antibodies as well as small molecule inhibitors in animal models of human CVD has provided a clear beneficial role for blocking complement C5, C5a, C5a receptor (C5aR1, CD88) and the soluble complement receptor 1 (sCR1) and different regulators at C3 convertase level. Moreover, the discovery of the second receptor for C5a, the C5aR2 (C5L2, C5a receptor-like 2) and recent studies on the functional role in atherosclerosis has raised the intriguing possibility of the use of this receptor as a novel anti-inflammatory strategy. Though work is still in progress to determine whether there is a global effect of this receptor in pathogenesis of cardiovascular disease, there is no doubt that complement blocking strategies is an emerging field in medical pharmacology.

Keywords: Atherosclerosis, Cardiac and vascular remodelling, Cardiovascular disease, Complement inhibitors, Complement system and activation, Myocardial infarction.

Cardiovascular disease (CVD) is the leading cause of death worldwide and the underlying pathological condition has been primarily attributed to atherosclerosis. It is well established that atherosclerosis is a chronic inflammatory process of the arterial vessel wall orchestrated by variety of mediators of innate and adaptive immunity [1, 2]. As a major and crucial component of both innate and adaptive immune system, the complement system maybe envisioned to have a pivotal role in the pathomechanisms of CVD. Indeed, substantial evidence supports complement-mediated pathogenesis of CVD through pleiotropic effects on multiple cell types strongly implicated in CVD [3, 4]. Several components of the complement system have been strongly associated with the outcome of cardiovascular events in patients [5 - 8]. Employing *in vitro* mechanistic studies and diverse *in vivo* models that mimic human CVD, the functional role of complement components in CVD has been established. In line with its well characterized pro-inflammatory effects, function in immune complexes and debris as well as apoptotic cells removal, the activation of the complement system has both beneficial and detrimental effects. Several studies using gene targeting, neutralizing antibodies and small molecule inhibitors have helped in identifying specific complement components harboring therapeutic potential. In this chapter,

we discuss both established and emerging paradigms in complement-mediated mechanisms underlying CVD. We summarize naturally occurring complement inhibitors and regulators, at various levels of complement activation, which could be harnessed for the treatment of CVD.

1. COMPLEMENT ACTIVATION CASCADE AND PATHWAYS

Complement system was first reported in 1896 by Jules Bordet, who found that antibodies present in fresh serum assisted in bacterial killing, but serum heated at 56°C or higher lost this property [9, 10]. The complement system, part of the innate and adaptive immune system, is usually regarded as the primary host-defense mechanism against pathogenic infections [11, 12]. This system is considered to be part of the primitive defense mechanism coordinating innate and adaptive immune systems [11, 13]. The mammalian complement system consists of more than 50 circulatory and membrane bound proteins. These proteins aid in differentiating between host and pathogen. Once a foreign body is detected by these proteins, they interact with one another and form immune complexes thereby aiding in pathogen clearance [14, 15]. The complement cascade can be activated by at least three major pathways - 1) Classical pathway 2) Lectin pathway and 3) Alternate pathway [16, 17]. The simplified version of the three pathways is depicted in Fig. (1). Additionally, the proteolytic enzymes in the newly described extrinsic protease pathway cleave C3 and C5 independent of conventional convertases. Furthermore, a new activation pathway exists for generation of C5a, especially in the absence of C3, with thrombin acting as a potent C5 convertase [16].

1.1. Classical Pathway of Complement Activation

The classical pathway of complement activation has always been regarded as the primary responder (major effector) to various stimulants such as Fc portion of immunoglobulin (Ig) in antigen-antibody complexes, enzymes like trypsin and numerous endotoxins, cell membranes, viruses and a string of other external stimulants [18]. It is the only complement pathway with functions in the adaptive immune system [19]. The classical pathway is activated when antibodies from pathogens are recognized and bound to multiple sites on the cell surface,

New Antiplatelet and Anticoagulant Agents: Towards Recognition and Reduction of Gastrointestinal Harm

Parth J. Parekh^{1,*}, Edward C. Oldfield I.V.² and David A. Johnson³

¹ Department of Internal Medicine, Division of Gastroenterology and Hepatology, Tulane University, New Orleans, LA, USA

² Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA

³ Department of Internal Medicine, Division of Gastroenterology and Hepatology, Eastern Virginia Medical School, Norfolk, VA, USA

Abstract: The most important adverse effect of antiplatelet and anticoagulant therapy is the occurrence of bleeding. Gastroenterologists, cardiologists, and primary care physicians often find themselves balancing the benefits of antiplatelet and anticoagulant therapy with the risk of bleeding, namely gastrointestinal bleeding. While aspirin and warfarin have long been the mainstay of oral antiplatelet and anticoagulant therapy, respectively, recent discoveries of more precise targets for therapy have come to market in order to reduce the risk of cardiovascular events and overcome the well-known limitations that plague warfarin therapy (*e.g.* narrow therapeutic index, variable individual metabolic response, and numerous food and drug interactions). Despite the fact that these novel agents may increase the risk of gastrointestinal bleeding [1], their ease of use makes them more attractive than conventional agents. This review will provide an overview of the pharmacology of available antiplatelet agents and anticoagulants, outline risks that clinicians should be cognizant of when considering prophylactic therapy in order to reduce the risk of gastrointestinal toxicity, and provide up to date data on reversal agents that are currently available as well as those that are in the pipeline.

* **Corresponding author Parth J. Parekh:** Department of Internal Medicine, Division of Gastroenterology and Hepatology, Tulane University, New Orleans, LA, 70112, USA; Tel: (504)988-5606; Fax: (504)988-2188; E-mail: parthjparekh@gmail.com

INTRODUCTION

Gastrointestinal bleeding (GIB) is a known adverse effect of antiplatelet agents [2]. and anticoagulants [1]. with significant morbidity and mortality in addition to an enormous burden on global health care resources [3]. The mean hospital cost for an episode of upper GIB, lower GIB, or small-bowel bleeding is upwards of \$7,300 USD, \$4,800 USD, and \$40,000 USD, respectively [3]. Expanding indications and ease of use have made antithrombotic therapy robust, which in turn has increased the burden of GIB related to these agents [4]. Antiplatelet agents (*e.g.* aspirin and thienopyridines) cause ulcers and erosions by inhibiting cyclooxygenase (COX)-1 resulting in prostaglandin depletion, which plays a pivotal role in maintaining the gastric epithelium [5]. In addition, antiplatelet agents impair angiogenesis and these two mechanisms in concert are thought to result in GIB. Traditional anticoagulants and novel oral anticoagulants (nOACs) (*e.g.* direct thrombin inhibitors or factor Xa inhibitors) are thought to precipitate bleeding from pre-existing lesions [1]. The nOACs may even predispose susceptible patients to a higher rate of GIB than traditional anticoagulants. Both of the landmark trials (Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) [6] and Rivaroxaban *versus* Warfarin in Nonvalvular Atrial Fibrillation (ROCKET-AF) [7]) that established the relative efficacy/non-inferiority of dabigatran and rivaroxaban, respectively, compared with warfarin therapy in selected patients demonstrated there to be an increased risk of GIB with these agents compared to warfarin therapy. Here, we review the pharmacology of available antiplatelet and anticoagulants, both traditional and nOACs, outline risk factors that warrant prophylactic therapy in order to reduce the risk of gastrointestinal toxicity, and review the most up to date literature on reversal agents that are currently available as well as those that are in the pipeline.

PHARMACOLOGY OF AVAILABLE ANTIPLATELET AGENTS

Aspirin

Aspirin irreversibly inhibits both COX1 and COX2 *via* serine acetylation. Aspirin achieves its antiplatelet properties through its effects on COX1-mediated thromboxane A₂, which is highly sensitive to aspirin [8]. Higher doses are

required for aspirin to exhibit its anti-inflammatory *via* inhibition of COX-2 mediated prostaglandin I₂ generation, thus larger daily doses at shorter dosing intervals are necessary in order to achieve its anti-inflammatory effects [8 - 10]. Fig. (1) depicts how differing doses of aspirin effect the COX pathway.




Fig. (1). Effect of differing doses of aspirin on the COX pathway.

Aspirin reaches its peak plasma concentrations within 40 minutes of ingestion, with notable platelet inhibition occurring within 1 hour [8]. Enteric-coated formulations have delayed onset, with peak plasma concentrations occurring within 4 hours after ingestion. Despite having a relatively short half-life of only 15 minutes, the effect of aspirin on platelets last for the entire lifespan of the platelet due to irreversible inhibition [8]. In addition, studies have also shown aspirin to effect COX1 on megakaryocytes (platelet precursors) thus affecting newly released platelets in addition to pre-existing ones [8, 10].

Thienopyridines– Clopidogrel, Prasugrel, and Ticagrelor

The thienopyridines and its derivatives are a group of antiplatelet agents that

SUBJECT INDEX

A

- ACE inhibition 67, 68, 77, 87
 ACE inhibitor and β -blockers 88, 93
 ACE inhibitors 66, 68, 70, 77, 78, 79, 81, 83, 84, 87, 88, 90, 94, 97, 105, 119, 120, 121
 benefits of 78, 105
 role of 79, 119, 120
 use of 121
 ACE inhibitors and diuretics 90, 118, 119
 ACE inhibitors for patients 77
 Acid 98, 99, 151, 152, 153, 154, 156, 259, 260
 alpha-linolenic (ALA) 98, 99
 amino 151, 152, 153, 154, 156
 folic 259, 260
 Activation of Gq protein 165, 166, 167
 Active metabolite 9, 13, 14, 17, 20, 30, 32, 33, 125, 358, 360
 Acute coronary syndrome (ACS) 3, 5, 10, 13, 16, 17, 20, 22, 38, 39, 78, 102, 103, 350, 352, 361
 Acute decompensated heart failure 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115
 Acute heart failure 62, 91, 109
 Acute myocardial infarction 79, 100, 313, 314, 316, 318
 Adenosine receptors 25
 Adhesion molecules 303, 304, 305, 312
 Adrenal gland 87, 165, 167, 170, 174
 Aldosterone antagonists 62, 87, 88, 94, 107, 122, 126
 Anaphylatoxins 284, 285, 288, 301, 306, 307, 313
 Andexanet alfa 368, 369
 Angioedema 79, 81
 Angiotensin-converting enzyme (ACE) 70, 77, 80, 81, 82, 88, 90, 93, 105, 107, 118, 119, 190
 Anti-aggregation therapy 4, 38, 44
 Anticoagulants 246, 347, 348, 361, 370
 Anticoagulation 15, 125, 246, 247, 248, 353, 365, 368
 Antidiuretic effects 150, 157, 168, 171, 172
 Antiplatelet 3, 4, 5, 9, 14, 17, 19, 28, 30, 125, 126, 248, 249, 348, 349, 350, 351, 353
 agents 3, 4, 5, 14, 28, 30, 248, 348, 349, 350, 351, 353
 effect 14, 17, 19
 therapy 9, 125, 126, 249
 Apixaban 358, 359, 360, 361, 362, 366, 368, 369
 Apoptosis 300, 301, 317
 Aquaporin 168, 169, 180
 Arginine 153, 154
 Arginine vasopressin 148, 149, 150, 152, 179
 Arrhythmias 86, 87, 103, 110, 112, 113, 182
 Arterial hypertension 219, 250
 Arteriosclerosis 219, 223, 224, 225, 226
 Aspirin 3, 5, 11, 15, 17, 19, 20, 44, 125, 126, 220, 249, 348, 349, 351, 352, 353, 354
 doses 349, 351
 effect 349
 use 351

Atherosclerosis 4, 225, 279, 280, 297, 303, 304, 305, 306, 307, 308, 309, 310, 320, 322
treatment of 307, 309
Atherosclerotic lesion 297, 305, 307
Atorvastatin 33, 100, 253
Atrial fibrillation 90, 91, 110, 112, 122, 125, 247, 248, 358, 359, 360, 361, 362, 363
Atrial natriuretic peptide (ANP) 153, 157, 158, 159, 163, 165, 173, 175
AVP/OT receptors 162, 168, 172

B

Baroregulation 157, 158
Barrier permeability, blood-brain 229, 240
Basal ganglia 225, 229, 236, 239
B-blocker initiation 72, 73
B-blockers 69, 71, 72, 73, 74, 75, 76, 78, 88, 93, 94, 95, 97, 100, 106, 118, 119
effects of 74, 75, 119
role of 73, 74, 106, 118
use of 75, 76
Beta-adrenergic receptors 112, 113
Beta blockers 62, 67, 68, 73, 79, 95, 112
BiDil 62
Binding of vasopressin receptors 171
Bleeding cangrelor 13
Bleeding rates 21, 24
Bleeding risk 40, 350, 359
Blood pressure 76, 84, 86, 95, 105, 107, 149, 157, 170, 174, 222, 234, 249, 250, 251, 252

systolic 86, 105, 234, 250, 251
Blood pressure control, intensive 251, 252
Bradycardia 72, 96
Brain atrophy 234, 236, 239, 240, 249
Brain stem 221, 222, 225
Brain volume 234, 239, 240, 242, 251
Bucindolol 70, 71, 74

C

Calcium channel blockers (CCBs) 32, 33, 42, 92, 121, 122, 258
cAMP 7, 45, 46, 111, 163, 165, 168, 171
Candesartan 81, 82, 117, 120
Cangrelor 4, 9, 13, 26, 27, 28, 45
Captopril 81, 82
Cardiac 65, 66, 77, 103, 110, 113, 123, 148, 149, 176, 179, 184, 187, 188, 189, 193, 312, 315, 319, 320
arrest 123, 148, 149, 176, 179, 187, 188, 189, 193
function 65, 66, 110, 315, 319, 320
output 65, 77, 103, 110, 113, 176, 184, 312
Cardiovascular
events 14, 98, 251, 279, 280, 298, 310, 311, 347, 350, 354, 355
major 310, 311
health study (CHS) 98
Catecholamines 158, 181, 182, 190, 191, 192
Cause cangrelor 13
Cells 4, 25, 168, 169, 171, 173, 284, 288, 289, 290, 291, 292, 300, 302, 304, 306

- red blood 4, 25, 289, 290, 292
- Cerebral amyloid angiopathy (CAA) 220, 223, 224, 226, 229, 261
- Cerebral artery 221, 222, 243, 250, 253
 - posterior 221, 222
- Cerebral blood flow (CBF) 240, 262
- Cerebral microangiopathy 220
- Cerebral microhaemorrhages 220, 227, 233
- Cerebrovascular reactivity 249, 253, 261
- CHAMPION trials 27
- Chemokines 286, 297, 298, 303, 304, 305
- Chronic heart failure 74, 87, 95, 96, 98, 105, 106, 111, 119, 126
- Chronic kidney disease (CKD) 45, 73, 79, 178, 352
- Chronic systolic heart failure 69, 70, 71, 72, 73, 74, 75, 76, 77, 79, 82, 83, 86, 87, 89
- Cloning 165, 167
- Clopidogrel 11, 12, 13, 17, 18, 19, 24, 27, 30, 32, 33, 38, 43, 44, 45, 350, 354
 - antiplatelet effect of 32, 33
 - high-dose 43
 - loading dose of 18, 27, 44
 - maintenance dose of 43, 44
- Clopidogrel 18, 31, 32, 33, 39, 40, 352
 - aspirin group 18
 - metabolism 32, 39, 40
 - therapy 18, 31, 39, 352
 - treated patients 33
 - use 352
 - users 33, 352
- Cobra venom factor (CVF) 315
- Cochrane database meta-analysis 257, 260
- Cognition 178, 239, 242, 249, 251, 254, 255, 256, 262
- Cognitive functions 178, 232, 251, 258, 259, 263
- COMMA trial 317
- Complement activation 280, 281, 282, 284, 287, 290, 299, 300, 301, 303, 305, 307, 309, 316, 317, 318, 319, 322
 - classical pathway of 281, 282
 - levels of 280, 281, 322
- Complement 279, 280, 281, 282, 283, 284, 286, 287, 289, 290, 295, 296, 299, 300, 301, 302, 303, 306, 307, 309, 310, 311, 312, 313, 315, 316, 319, 322
 - activation cascade 281, 287, 289, 295
 - cascade 279, 280, 281, 287, 302, 311, 317
 - components 280, 286, 296, 299, 300, 302, 306, 307, 310, 312, 322
 - factors 284, 311
 - inhibition 309, 310, 313, 315, 316, 319
 - receptor (CR) 280, 287, 290, 301, 302
 - system 279, 280, 281, 282, 283, 284, 296, 301, 302, 303, 306, 310, 311, 313, 322
- Computed tomography (CT) 231, 235, 236, 248
- Concomitant use of aspirin 352

- Convertases 282, 283, 284, 285, 288, 289, 290, 291, 292, 293, 294, 315, 316, 318
activity 289
level 280, 290, 292, 294
- Coronary artery disease (CAD) 3, 4, 5, 16, 43, 69, 78, 97, 98, 101, 102, 121, 310, 354
- Coronary vasodilation 176
- CORONA trial 101, 102
- Cortical 222, 223
perforators 222, 223
surface 222, 223
- Corticotrophin-releasing hormone (CRH) 167, 177
- Cough, inhibitor-related 80, 81
- CV death 11, 12, 24, 124
- Cysteine residues 151, 152
- D**
- Dabigatran 348, 357, 358, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369
users of 362, 363
- Dabigatran etexilate 357, 358
- Decompensation, acute 103, 105, 106, 126
- Deep brain infarcts (DBI) 220, 227, 229, 230, 231, 232, 233, 234, 236, 237, 239, 244, 245, 248, 249, 252
- Deep intracerebral haemorrhages (DIH) 220, 227, 228, 230, 232, 233, 236, 238
- Deep vein thrombosis (DVT) 359, 361
- Deficiency, relative vasopressin 181, 182
- Dementia 231, 232, 234, 244, 245, 246, 250, 251, 254, 255, 257, 258, 259, 260, 263, 264
senile 257, 259
- Diabetes insipidus 149, 150, 179, 180
- Diacylglycerol 165, 166, 167
- Diastolic dysfunction 62, 116, 119, 120, 122
- Diffusion tensor imaging (DTI) 241, 249
- Digoxin 62, 70, 80, 89, 90, 91, 92, 93, 94, 96, 107, 110, 117, 119, 122
- Disease 220, 224, 229, 244, 254, 256, 258, 308, 309, 320, 322
Alzheimer's 220, 224, 229, 244, 254, 256, 258
inflammatory 308, 309, 320, 322
- Diuresis 65, 84, 85, 104, 114, 164
- Diuretic response 85
- Dobutamine 62, 110, 111, 112
- Donepezil 254, 255
- Drugs 14, 32, 93, 97, 125, 220, 250, 254, 255, 256, 257, 313, 322, 361, 369, 370
antihypertensive 250
- Dual anti-platelet therapy (DAPT) 3, 4, 5, 15, 19, 39, 43, 44, 45
- Dysarthria 230, 232
- Dysfunction 73, 74, 92, 98, 99, 108, 122, 241, 253, 298
endothelial 92, 98, 99, 122, 241, 253, 298
right ventricular 73, 74, 108
- Dyspnea 25, 26, 29, 103, 109, 110, 112, 113, 116

self-reported 109, 110

E

Eculizumab 293, 296, 316, 318

Ejection fraction 66, 70, 72, 74, 78, 79, 80, 81, 82, 83, 88, 90, 91, 93, 95, 99, 113, 116, 118, 119

left ventricular 72, 74, 78, 81, 88, 91, 99

Elinogrel 4, 9, 28, 29, 44, 45

Enalapril 78, 80, 81, 82, 92, 93, 120

Endothelial cell (EC) 36, 170, 177, 286, 289, 294, 296, 27, 298, 299, 304, 305, 308, 321

Endpoints mortality MI stroke 12, 13

Enlarged perivascular spaces 220, 227, 228, 234, 236, 239

Epidural anaesthesia 189, 190

Epinephrine 176, 186, 187, 188, 189, 193

Eplerenone 68, 87, 88, 89, 122

Erythrocytes 290, 291, 293

European atrial fibrillation trial (EAFT) 247

European society of cardiology (ESC) 39, 96, 97, 106

Exercise capacity 90, 97, 117, 119, 121, 123

Existing form and expression 288, 290, 291, 292, 293, 321

F

Factor 156, 366, 367, 368, 369, 371

eight inhibitor bypass activity (FEIBA) 367, 368, 369, 371

PCC 368

chromogenic 366, 369

affecting vasopressin release 156

Fibrate therapies 251

Fibrinoid 219, 224, 225, 226, 228

necrosis 219, 224, 225, 226, 228

necrosis and lipohyalinosis 225, 226, 228

Flow cytometry 31, 34, 35, 36

Fluid retention 66, 83, 85, 86, 87

Food and drug administration (FDA) 14, 76, 97, 366, 367

Fractional anisotropy (FA) 241, 242, 249

Full anticoagulation versus aspirin and ticlopidine (FANTASTIC) 15

Furosemide 84, 85, 104, 120

G

Galantamine 254, 255

Gastrointestinal 15, 17, 347, 348, 351

Gastrointestinal injury 351, 353, 355, 356

Genetic testing 4, 32, 41

GIB 348, 351, 352, 354, 359, 360, 361, 362, 363, 364, 365, 370

increased risk of 348, 352, 360, 361, 362, 363

lower 348, 352

risk for 360, 361, 362, 364, 365

risk of 351, 352, 360, 361, 362, 363, 364, 370

GISSI-HF 99, 101

- G-proteins 8, 46, 162, 167, 171, 174, 308
- H**
- Haemorrhages 221, 232, 236, 238, 247
- Heart decompensation 62
- Heart disease, valvular 65
- Heart failure 63, 64, 67, 83, 84, 89, 96, 102, 106, 107, 108, 110, 112, 115, 116, 172
- acute de-compensated 107, 108
- congestive 63, 64, 67, 83, 84, 89, 172
- decompensated 106, 108, 110, 112, 115, 116
- hospitalization for acute decompensated 102, 106, 107
- treatment of acute decompensated 115
- treatment of chronic 96
- Heart failure medications 72, 73, 87
- Heart failure patients 75, 76, 90, 91, 122, 126
- chronic systolic 75, 76, 90, 122, 126
- symptomatic chronic systolic 91
- Heart failure symptoms 70, 72, 78, 90, 91, 125
- Heart failure therapies 74, 93, 94, 119
- conventional 119
- standard 74, 93, 94, 119
- Heart failure treatment, standard 74, 93, 102
- Heart rate reduction 72, 95, 97
- Hemodialysis 45, 353, 367, 368, 369
- Hemodynamics 65, 66, 84, 108, 110, 193
- Hemorrhagic shock 160, 161, 185, 186, 193
- HF hospitalizations 80, 81, 82, 117
- HFpEF patients 119, 121, 122, 126
- High on-treatment platelet reactivity 4
- Hippocampus 165, 167, 170, 229, 239
- H. pylori* eradication 355, 356
- H. pylori* treatment 356
- Human vasopressin 150, 152
- amino acid sequence of 152
- Hydralazine 70, 92, 93, 94, 95
- combination 92, 93, 94
- Hyperkalemia 79, 89, 106, 107
- Hypertension 77, 79, 81, 84, 97, 116, 118, 121, 122, 232, 234, 237, 248, 251, 263
- Hypertensive patients 86, 237, 252
- high-risk 86
- Hyponatremia 86, 104, 190, 192
- Hypotension 79, 86, 87, 95, 105, 106, 108, 109, 110, 111, 112, 113, 189, 190, 191
- Hypothalamus 150, 151, 155, 157, 165, 170, 178, 180
- Hypovolemia 156, 158, 173, 181
- I**
- Ibopamine 62, 124, 125
- group 124, 125
- Idarucizumab 367, 369
- Immune 280, 281, 296, 297, 311
- complexes 280, 281, 296, 297, 311
- system, adaptive 280, 281
- Inhibitors 83, 123, 124, 220, 254, 256, 348, 357, 368
- acetylcholinesterase 220, 254, 256

direct renin 123, 124
direct thrombin 348, 357, 368
neprilysin 83
Inhibitors/angiotensin receptor 77, 105, 119
Inositol triphosphate 165, 166, 167
Inotropes 110, 111, 112, 182
Inotropic therapies 107
Integrin α IIb β 3 activation 6, 7, 8
Internal capsule 221, 230, 235, 236
International normalized ratio (INR) 15, 247, 356
Intracerebral haemorrhages 219, 220, 227, 228, 230, 232, 234, 236, 238, 247, 248, 318
 deep 220, 227, 228, 230, 232, 236, 238
Intranasal 178, 179
Ischemic event 4, 17, 37, 39, 42, 248, 252, 310
Ischemic heart disease 92, 93, 101, 102, 316
Ischemic stroke 11, 16, 230, 231, 234, 246, 247, 248, 252, 262
Isosorbide dinitrate 92, 93, 94, 95
 combination of 92, 94, 95
Ivabradine 62, 95, 96, 97
IV infusion 178, 179

L

Lacunar infarcts 221, 226, 227, 228, 230, 231, 235, 236, 239
Lacunar stroke 219, 220, 234, 240, 245, 249, 250, 252, 253
Lacunae 219, 227, 228, 231, 236, 243, 260, 262

Left ventricular (LV) 71, 72, 74, 75, 77, 78, 81, 88, 91, 97, 99, 100, 113, 116, 312
Left ventricular dysfunction 74, 78, 79, 81, 92, 93, 95, 100
Leukoaraiosis 219, 220, 231, 233, 234, 235, 237, 240, 241, 246, 247, 248
Levels 91, 92, 245, 310
 serum 92, 245, 310
 serum digoxin 91, 92
Levosimedan Infusion versus Dobutamine (LIDO) 112
Levosimendan 111, 112
Lipohyalinosis 224, 225, 226, 228
Loop diuretics 84, 85, 87, 104
Low-density lipoprotein (LDL) 303, 304
Low on-treatment platelet reactivity 4, 38
Lysine-vasopressin 153

M

Macrophages 225, 233, 286, 290, 292, 294, 296, 300, 301, 302, 303, 304, 306, 307, 308
Magnetic resonance imaging (MRI) 221, 233, 235, 236, 237, 239, 241, 242, 243, 244, 249, 252, 261, 262
Magnetisation transfer ratio (MTR) 242
Major bleeding Clopidogrel 11
Major bleeding Prasugrel 11, 12
Major bleeding Ticagrelor 12
Major GIB 351, 352, 359, 360, 362
Mannose-Binding Lectin (MBL) 283, 302, 303, 310, 311, 319
Mast cells 285, 303, 305, 306

- Mean arterial pressure (MAP) 114, 182, 183
- Membrane attack complex (MAC) 283, 284, 289, 292, 293, 296, 298, 300, 301, 307, 311, 312, 316, 318
- Metolazone 85, 104
- Metoprolol succinate 70, 75, 76
- Metoprolol tartrate 70, 73, 76
- Microaneurysms 224, 225, 226, 227
- Microatheromas 219, 224, 225
- Microbleeds 228, 230, 233, 234, 236, 238, 243, 249
cerebral 228, 230, 233, 238
- Microhaemorrhages 219, 227, 228, 233, 240
- Microns 222, 223, 225, 226
- Migration inhibitory factor (MIF) 304, 305
- Mini-mental state examination (MMSE) 231, 256, 258, 259
- Models 63, 65, 67, 68, 176, 298, 300, 315, 319
neurohormonal 67, 68
- Molecular formula 152, 153, 154
- Monocytes 36, 288, 291, 292, 297, 299, 304, 312
- Mortality 74, 75, 77, 78, 79, 80, 81, 82, 83, 94, 100, 102, 106, 110, 183
- Mortality benefit 67, 68, 70, 71, 72, 75, 79, 83, 86, 87, 90, 93, 95, 101, 102
- Mortality rates 73, 93, 101, 231, 311
cumulative 93
- Mortality reduction 66, 77, 79
- Mortality risk 92, 93
- Myocardial contractility 65, 69, 95, 96, 111, 113
- Myocardial infarction (MI) 11, 12, 13, 17, 18, 21, 22, 24, 38, 80, 310, 311, 312, 318, 320
- N**
- N-3 PUFA, marine 98, 99
- Natriuretic peptides 62, 109
- Nebivolol 71, 75, 118
- Nesiritide 109, 110
- Neurohormonal activation 87, 108
- Neutrophils 36, 285, 286, 290, 292, 297, 305, 308, 313, 321
- New P2Y₁₂ Inhibitors 30, 41, 42
- Nitric oxide 92, 94, 159, 165, 171
- Nitroglycerin 108, 109
- Nocturnal enuresis 178, 179
- Non-CABG 11, 12, 38
- Norepinephrine 110, 157, 158, 159, 171, 173, 182, 183, 184, 185, 191
- North American symptomatic carotid endarterectomy trial (NASCET) 248
- Novel therapies 62
- NSAID-related gastrointestinal injury 353
- NSAID use 355
- O**
- Omeprazole 33, 354, 355
- Osmoregulation 156, 157, 172
- Oxytocin 150, 151, 153, 162, 164, 165, 169
- Oxytocin receptor 148, 149, 163, 169

P

- Paroxysmal nocturnal hemoglobinuria(PNH) 289, 296, 318, 319
- Pathways 281, 283, 287, 288, 292, 293, 295, 296, 313, 319
- lectin 281, 283, 287, 288, 295, 313, 319
- terminal 292, 293, 296
- PCI patients on clopidogrel 38
- Peptide release, atrial natriuretic 153, 170
- Peptides 151, 152, 153, 259, 285
- Percutaneous coronary intervention (PCI) 3, 4, 5, 18, 22, 27, 29, 37, 38, 39, 43, 44, 45, 350
- Perindopril 117, 120, 250, 252
- Pexelizumab 293, 296, 310, 316, 317, 318, 319
- Phagocytosis 288, 290, 291, 292
- Pharmacologic therapies 63, 67, 68
- Phospholipase 165, 166, 167, 170
- Phosphorylation 7, 8, 171, 286
- Pituitary 148, 150, 151, 156, 159, 160, 164, 171, 173, 174
- posterior 150, 151, 156, 159, 160, 173, 174
- Placebo-controlled clinical trial 258
- Placebo groups 18, 26, 124
- Plaque formation, atherosclerotic 303, 304, 306, 309
- Plasma osmolality 148, 149, 157, 158, 159, 180
- regulation of 148, 149
- Plasma proteins 225, 279, 288, 315
- Plasma vasopressin levels 156, 161
- Platelet aggregation 4, 7, 8, 9, 14, 15, 20, 23, 26, 30, 35, 37, 41, 45, 164
- Platelets 3, 4, 5, 6, 7, 8, 20, 23, 26, 31, 32, 33, 34, 35, 36, 37, 38, 39, 42, 43, 45, 161, 164, 165, 166, 177, 245, 298, 300, 302, 349, 350, 352
- aggregometry 34
- analyzer 31, 36
- counting 32, 34, 37
- derived growth factor (PDGF) 298, 300, 352
- function 20, 23, 26, 33, 36, 37, 39, 43, 249
- function tests 34, 39
- inhibition 28, 30, 33, 39, 42, 349, 350
- inhibition and patient outcome 23
- microparticles 245, 302
- P2Y12 receptor 3, 45
- reactivity 4, 5, 35, 37, 38, 43, 45
- index (PRI) 35, 38
- Polyunsaturated Fatty Acids (PUFA) 97, 98, 99
- Prasugrel 9, 10, 11, 12, 19, 20, 21, 22, 23, 30, 42, 43, 44, 350, 352
- cause 11, 12
- efficacy/safety of 22
- Prasugrel group 21, 22
- Preserved ejection fraction 62, 68, 69, 71, 116, 117, 119, 122, 123, 126
- Pressure 74, 84, 109, 113, 114
- pulmonary capillary wedge 74, 84, 109, 113, 114
- right atrial 113, 114

Pretreat, major bleeding 12
Protein-coupled receptors 7
Protein kinase 8, 162, 163, 165, 167, 168
Proteins, membrane cofactor 287, 290
Prothrombin complex concentrate(PCC) 367, 368, 369, 371
Proton pump inhibitors (PPIs) 32, 33, 42, 353, 354, 355
Provasopressin 155, 156
P-selectin 36, 249, 294, 298, 299, 302, 304, 305
Pulmonary capillary wedge pressure (PCWP) 74, 84, 109, 113, 114
Pulmonary embolism (PE) 359
Pulsatility index 243, 250
Pulseless electrical activity (PEA) 187, 188
Purinergic receptors 148, 170, 171

R

RAAS blocker and β -blocker 96, 97
RALES trial 87, 89
Rates, glomerular filtration 89, 114, 156
Receptor antagonists 3, 4, 5, 22, 36, 97, 107, 122, 125
 mineralocorticoid 97, 107, 122, 125
Receptor antagonists anti-platelet action 3, 5
Receptor for C5a 280, 286, 287, 297, 308, 322
Receptors, anaphylatoxin 306, 307
Relaxin 115, 220, 263
Remodeling, vascular 299, 300, 323
Renal collecting ducts 164, 168, 169

Renal dysfunction 73, 74, 77, 109, 111
Renal function 39, 73, 82, 84, 89, 91, 105, 107, 114, 370
Renin angiotensin aldosterone system (RAAS) 66, 67, 77, 87, 120, 121, 190
Resistance indexes 219, 243
Restricted leukoaraiosis 248
Reversal agents 347, 348, 366, 368, 369, 370
Risk factors 219, 224, 233, 237, 240, 246, 247, 248, 251, 264, 352, 363
 classical vascular 219, 264
 independent 247, 248, 352, 363
 vascular 224, 233, 237, 240, 246, 251
Risk of ulcer 355
Rivaroxaban 348, 358, 359, 360, 361, 362, 363, 366, 368, 369
 and apixaban 358, 366, 368
Rivastigmine 254, 256

S

Selective serotonin reuptake inhibitors (SSRIs) 352
Sensitive receptor Gi-coupled 6
Sepsis 148, 149, 158, 159, 160, 161, 171, 172, 176, 177, 181, 182, 183, 184, 185, 192, 294, 308, 309, 322
 shock 149, 158, 159, 160, 161, 172, 176, 177, 181, 182, 183, 184, 185, 192
Sinoatrial node 95, 96
Sites, absent vasopressin receptor 180
Small vessel diseases 220, 224, 239, 244, 246, 264

cerebral 223, 224, 225
SMCs, neointimal 299
Smooth muscle cells (SMCs) 23, 150, 164, 165, 166, 173, 175, 219, 225, 226, 258, 286, 296, 300, 304, 306
vascular 23, 150, 164, 165, 166, 173, 175
Spironolactone 68, 86, 87, 88, 89, 122, 123
Statins, mortality benefit of 102
ST-elevation MI (STEMI) 11, 12, 13, 18, 21, 25, 313, 317
Stent implantation 3, 4, 5, 18
Stent thrombosis 21, 27, 37, 38, 41, 43, 44, 45
Stimulation of vasopressin receptors 162
Stroke, non-fatal 16, 21, 126
Stroke Clopidogrel 11
Stroke Prasugrel 11, 12
Stroke prevention, secondary 248, 249, 250, 252
Stroke prevention by aggressive reduction of cholesterol levels (SPARCL) 253
Subcortical ischaemic strokes 224
Subendothelial space 303, 304
Surrogate markers 234, 235, 237, 244
Sympathetic nervous system (SNS) 66, 67, 69, 189
Systolic dysfunction 73, 74, 78, 81, 87, 88, 92, 96, 97, 100, 101, 107, 113, 116, 122
Systolic dysfunction, left ventricular 78, 81, 88, 96, 97, 100, 113, 116
Systolic heart failure 74, 75, 78, 79, 85, 87, 88, 90, 92, 94, 96, 101, 102

T

Terlipressin 149, 153, 154, 179, 181, 184, 186, 188, 189, 192
Thienopyridines 9, 13, 14, 28, 348, 349, 350, 352
Thienopyridines– Clopidogrel 349, 352
Thrombelastography 34, 37
Thrombin time (TT) 365, 366, 368, 369, 370, 371
Thrombosis bleeding 11, 12, 13
Thromboxane A2 4, 6, 8, 36, 46, 306
Thrombus formation 3, 4, 9, 304
Ticagrelor 9, 12, 22, 23, 24, 25, 26, 27, 28, 30, 42, 45, 349, 350, 352
group 24, 25
therapy 25
Ticlopidine 9, 14, 15, 16, 17, 19, 43, 220, 249
Ticlopidine aspirin stroke study (TASS) 16
Ticlopidine group 16
Tissue factor (TF) 298, 302
Torsemide 84, 85, 104
Trail making test (TMT) 256, 263
The transcranial doppler (TCD) 242, 243, 244
Transmembrane pore 283, 284

U

Undergoing PCI 16, 20, 21, 27, 37, 38, 43, 45
Upper GIB 348, 351, 352, 353, 354
risk of 351, 353, 354
Urine output 149, 167, 180, 182

V

Val-HeFT trials 100

Vascular dementia 220, 221, 226, 240, 244, 254, 255, 256, 257, 258, 259, 260

probable 254, 255, 256
trials 254, 257

Vascular 122, 298, 299, 301, 307, 308, 309

inflammation 122, 298, 307, 308
injury 299, 301, 308, 309

Vascular smooth muscles cells (VSMCs) 296, 299, 300, 301, 321

Vasoconstriction 150, 164, 165, 166, 170, 173, 175, 176, 186

Vasodilation 108, 115, 148, 150, 164, 165, 166, 168, 169, 170, 173, 175, 176, 182, 186

Vasodilatory shock 148, 149, 167, 173, 176, 179, 181, 185, 191, 192, 193
states 173, 179, 181, 192

Vasopressin 148, 149, 150, 151, 153, 156, 160, 161, 164, 175, 176, 177, 178, 180, 181, 182, 183, 187, 188, 189

actions of 150, 175
amino acid sequences of 150
doses of 178, 180, 181
effects of 177, 183
efficacy of 187, 188, 189
endogenous 148, 156
exogenous 156, 164
high levels of 160, 161
low-dose 176, 182
relative deficiency of 149, 182
structure of 150, 151

supraphysiological doses of 153, 177

Vasopressin 108, 159, 160, 161, 176, 182, 183, 184, 185, 188, 189, 192, 193

and septic shock trial (VASST) 161, 182, 183, 192

and terlipressin in pediatric patients 184

antagonists 108

-epinephrine use, combined 188, 189
infusion 160, 176, 182, 185, 192, 193

production 159, 160, 161

Vasopressin levels 156, 157, 158, 160, 161, 184, 187

circulating 156, 157, 158, 161

Vasopressin receptors 149, 151, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 171, 173, 179, 180, 183, 185, 186, 188, 189, 191, 192, 193

classic 149

renal 163

physiology 164

release 156, 157, 158, 159, 171

action 180

secretion 157, 158, 159, 160, 161, 173, 179

synthesis 155, 156, 160

therapy 183, 185, 186, 188, 189, 191, 192, 193

Vasopressor 72, 154, 182, 183, 186, 191, 193

agents 183, 191

drugs 186

effects 154, 182

therapy 72, 193

Ventricular fibrillation (VF) 148, 176,
179, 187, 188
Verapamil 117, 121
Vessels 166, 173, 221, 222, 223, 228,
229, 243
Vitamins 260, 262, 356

W

Walls, arterial 225, 226, 229
Warfarin 15, 125, 126, 247, 347, 348,
356, 357, 359, 360, 361, 362, 363,
364, 365, 366, 370
therapy 348, 359, 360, 365, 366, 370

White matter 219, 220, 221, 223, 225,
227, 228, 229, 230, 231, 232, 233,
235, 236, 237, 238, 240, 241, 242,
243, 244, 250, 262
lesions (WML) 219, 220, 221, 227,
228, 230, 231, 232, 233, 236, 237,
243, 244, 250, 262
tracts 240, 241, 242
Widespread leukoaraiosis 248
Worsening heart failure 90, 97, 106,
114, 122



PROF. DR. ATTA-UR-RAHMAN, FRS

Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has 1020 international publications in several fields of organic chemistry including 727 research publications, 37 international patents, 68 chapters in books and 188 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world's leading encyclopedic series of volumes on natural products "Studies in Natural Product Chemistry" 50 volumes of which have been published under his Editorship by Elsevier during the last two decades.

Prof. Rahman won the UNESCO Science Prize (1999) and was elected as Fellow of the prestigious Royal Society (London) in July 2006. He has been conferred honorary doctorate degrees by many universities including (Sc.D.) by the Cambridge University (UK) (1987). He was elected Honorary Life Fellow of Kings College, Cambridge University, UK, conferred the TWAS (Italy) Prize and the Austrian government has honoured him with its high civil award ("Grosse Goldene Ehrenzeischen am Bande") (2007). He is Foreign Fellow of Chinese and Korean Academy of Sciences, Foreign Fellow of the Chinese Chemical Society and former President of Pakistan Academy of Sciences.



PROF. DR. M. IQBAL CHOUDHARY

Dr. M. Iqbal Choudhary is a Professor of Organic/ Bioorganic Chemistry and Director at the International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research). He is among the most prominent scientists of Pakistan, recognized for his original contributions in the fields of natural products and bioorganic chemistry. He has written and edited 27 books, most of which have been published in USA and Europe. He is also the author of over 900 research papers and chapters in top international science journals of the West as well as 27 US patents. The cumulative impact factor of his publication is over 1,650. This is by far the largest number of quality publications from any scientist in Pakistan. He has been among the most cited scientists of Pakistan in last five years with citations exceeding 7,900 (h-Index: 33). He is the Volume Editor of many international book series and journals. He has served as a visiting faculty in many prestigious universities of the world including Cornell University (New York), Purdue University (Indiana), Pennsylvania State University (Pennsylvania), Scripps Institution of Oceanography (San Diego, California), The University Rhode Island (Rhode Island), and various top Universities of UK, Saudi Arabia, Malaysia, Kazakhstan and Iran.